Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. ACC Action Center

Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD

Michael Gibson at the ACC24
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    ACC.24 - A structured approach to treat hypercholesterolemia with an "inclisiran first" strategy in US patients with ASCVD performs much better than usual care, according to Michael Koren. He hopes that the results of VICTORION-INITIATE are a wake-up call to treat patients more aggressively with lipid-lowering therapies. 

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Michael Koren, MD is is a practicing cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research , Jacksonville, FL, US.

  • Disclaimer

Recommended
Details
Presenters
Comments
  • Overview

    ACC.24 - A structured approach to treat hypercholesterolemia with an "inclisiran first" strategy in US patients with ASCVD performs much better than usual care, according to Michael Koren. He hopes that the results of VICTORION-INITIATE are a wake-up call to treat patients more aggressively with lipid-lowering therapies. 

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Michael Koren, MD is is a practicing cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research , Jacksonville, FL, US.

  • Disclaimer

Schedule6 Oct 2024